Bay­er inks up with “small” In­di­an biotech for new ap­proach at an old tar­get

Cu­radev, the self-ad­mit­ted­ly “small” In­di­an biotech, has racked up an­oth­er big-name part­ner­ship.

Bay­er has promised up to €250 mil­lion ($267 mil­lion) in biobucks for ac­cess to Cu­radev’s STING plat­form, the same one that Take­da jumped in on last May. The deal gives Bay­er rights to treat­ments for a se­ries of lung, car­dio­vas­cu­lar and in­flam­ma­to­ry dis­eases. Take­da had li­censed the lead mol­e­cule from that plat­form, an an­ti­body drug con­ju­gate for im­muno-on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER